Tel. 913303861
San Carlos Clinical Hospital
C/ Profesor Martín Lagos s/n. 28040-Madrid
The “Cell differentiation and gene expression” group is part of the Haematology Department of the Hospital Clínico San Carlos and is part of the Health Research Institute (Instituto de Investigación Sanitaria) San Carlos (IdISSC). The focus of its research is gene regulation in the process of erythro/megakaryocyte differentiation and platelet properties in healthy conditions and in myeloproliferative neoplasms (MPN). For this reason, it has the collaboration and support of the Haematology Department of the Hospital Clínico San Carlos (Dr. Rafael Martínez Martínez, Dr. Celina Benavente Cuesta, and Dr. Fernando Ataúlfo González Fernández).
In addition, the group collaborates with several national health research groups (Hospital del Mar, Barcelona, and the University Hospital of Valencia, INCLIVA) under the coordination of the Spanish Group of Philadelphia Negative Chronic Myeloproliferative Diseases (GEMFIN) and at international level (Department of Haematology, UZLeuven, Leuven, Belgium) to carry out studies with patients with essential thrombocythemia (ET) and primary myelofibrosis (PMF).
The laboratory implements new techniques for primary cell culture (megakaryocytes and erythrocytes) and has integrated new technologies for mass sequencing (RNA-seq in single cells and mutational analysis), proteomics (mass spectrometry), and platelet functional assays based on flow cytometry (in collaboration with Dr. L. Gutiérrez -ISPA University of Oviedo-) to generate databases of all patient groups (JAK2V617F, MPLW515K/L, CALR Type I & II, and triple-negative) and identify molecular markers with diagnostic/prognostic value in the clinic.
To characterise at the molecular level the pathology of myeloproliferative neoplasms (MPN), especially essential thrombocythemia (ET) and primary myelofibrosis (PMF). Using a multidisciplinary approach, we aim to connect clinical and basic research and form a core of work that works in both directions to improve our knowledge of fundamental processes at the cellular level (megakaryopoiesis and thrombopoiesis) and their alterations in MPN patients that could be associated with thrombosis and haemorrhage in these patients. Thus, we will try to personalise the treatment according to the individual characteristics of the patients.
FUNDING
